Outlook is neutral, with stock confined to a span of ±7%
Strategy has +29% ROI potential and 17% overvalued
MRNA Moderna35.09-0.12 (-0.3%)
Bullish play with a target stock price of $32.50 or above
Strategy has +32% upside potential and 102% overvalued
MRNA Moderna30.99-0.10 (-0.3%)
MRNA Moderna35.12+1.39 (+4.1%)